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MPA (mycophenolic acid) is an immunosuppressive drug
produced by several fungi in Penicillium subgenus Penicillium.
This toxic metabolite is an inhibitor of IMPDH (IMP
dehydrogenase). The MPA-biosynthetic cluster of Penicillium
brevicompactum contains a gene encoding a B-type IMPDH,
IMPDH-B, which confers MPA resistance. Surprisingly, all
members of the subgenus Penicillium contain genes encoding
IMPDHs of both the A and B types, regardless of their ability
to produce MPA. Duplication of the IMPDH gene occurred
before and independently of the acquisition of the MPA-
biosynthetic cluster. Both P. brevicompactum IMPDHs are
MPA-resistant, whereas the IMPDHs from a non-producer
are MPA-sensitive. Resistance comes with a catalytic cost:
whereas P. brevicompactum IMPDH-B is >1000-fold more
resistant to MPA than a typical eukaryotic IMPDH, its kcat/Km
value is 0.5% of ‘normal’. Curiously, IMPDH-B of Penicillium
chrysogenum, which does not produce MPA, is also a very poor
enzyme. The MPA-binding site is completely conserved among
sensitive and resistant IMPDHs. Mutational analysis shows that
the C-terminal segment is a major structural determinant of
resistance. These observations suggest that the duplication
of the IMPDH gene in the subgenus Penicillium was permissive
for MPA production and that MPA production created a selective
pressure on IMPDH evolution. Perhaps MPA production rescued
IMPDH-B from deleterious genetic drift.
Key words: drug resistance, gene duplication, IMP dehydrogenase
(IMPDH), mycophenolic acid, neofunctionalization, Penicillium.
INTRODUCTION
Filamentous fungi produce a vast arsenal of toxic natural products
that require the presence of corresponding defence mechanisms
to avoid self-intoxication. The importance of these defence
mechanisms is demonstrated by the presence of resistance
genes within biosynthetic gene clusters, yet how production
and resistance co-evolved is poorly understood. Insights into
the inhibition of enzymes involved in self-resistance provide
an intriguing strategy for the development of antifungal agents.
Furthermore, the elucidation of the defence mechanisms is
required for the design of heterologous cell factories producing
bioactive compounds.
Self-resistance can involve expression of a target protein that
is impervious to the toxic natural product, which suggests
that resistance originates from a gene-duplication event. The
biosynthetic cluster of the immunosuppressive drug MPA
(mycophenolic acid) offers an intriguing example of this
phenomenon. MPA is a well-characterized inhibitor of IMPDH
(IMP dehydrogenase) [1], and the Penicillium brevicompactum
MPA-biosynthetic cluster contains a second type of IMPDH gene
that confers MPA resistance (IMPDH-B/mpaF) [2,3]. Curiously,
both MPA producers and non-producers in Penicillium subgenus
Penicillium contain two IMPDH genes encoding IMPDH-A
and IMPDH-B [3]. Phylogenetic analysis suggests that the
gene-duplication event occurred before or simultaneous with
the radiation of Penicillium subgenus Penicillium [2,3]. How
this gene-duplication event influenced the acquisition of MPA
biosynthesis is not understood.
In the present study, we investigated the relationship between
MPA production, MPA resistance and the properties of IMPDH-A
and IMPDH-B. Whereas IMPDH-B from the producer organism
P. brevicompactum is extraordinarily resistant to MPA, IMPDH-
B from the non-producer Penicillium chrysogenum displays
typical sensitivity. Both IMPDH-Bs are very poor enzymes,
but P. chrysogenum IMPDH-B is almost non-functional. These
observations suggest that acquisition of the MPA biosynthetic
cluster may have rescued IMPDH-B from deleterious genetic
drift.
EXPERIMENTAL
Fungal strains
P. brevicompactum IBT23078, P. chrysogenum IBT5857,
Aspergillus nidulans IBT27263, and the 11 strains listed in
Supplementary Table S1 (at http://www.BiochemJ.org/bj/441/
bj4410219add.htm), were grown on CYA (Czapek yeast extract
agar) at 25 ◦C [4].
MPA treatment of fungi
Spores from P. brevicompactum IBT23078, P. chrysogenum
IBT5857 and A. nidulans IBT27263 were harvested and
suspended in sterile water. Then, 10 μl of serial 10-fold spore
dilutions were spotted on to CYA plates with or without 200 μg/ml
MPA. All plates contained 0.8% methanol. Stock solution
(25 mg/ml MPA in methanol) and MPA plates were made briefly
Abbreviations used: CYA, Czapek yeast extract agar; dPCR, degenerate PCR; DTT, dithiothreitol; gDNA, genomic DNA; IMPDH, IMP dehydrogenase;
AnImdA, IMPDH-A from Aspergillus nidulans; PbIMPDH-A, IMPDH-A from Penicillium brevicompactum; PbIMPDH-B, IMPDH-B from P. brevicompactum;
PcIMPDH-A, IMPDH-A from Penicillium chrysogenum; PcIMPDH-B, IMPDH-B from P. chrysogenum; IPTG, isopropyl β-D-thiogalactopyranoside; LB,
Luria–Bertani; MPA, mycophenolic acid.
1 Present address: Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark.
2 Present address: Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215-252, U.S.A.
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before the spores were spotted on to the plates in order to avoid
MPA degradation. MPA was acquired from Sigma.
RNA purification and cDNA synthesis
Spores from P. brevicompactum IBT23078 were harvested and
used to inoculate 200 ml of YES (yeast extract sucrose) medium
in 300 ml shake flasks without baffles [4]. P. brevicompactum
was grown at 25 ◦C and 150 rev./min shaking. After 48 h, the
mycelium was harvested and RNA was purified using
the Fungal RNA purification Miniprep Kit (E.Z.N.A.) and cDNA
was synthesized from the RNA using Finnzymes PhusionTM RT
(reverse transcription)–PCR kit following the instructions of the
two manufacturers.
Plasmid construction
Constructs for expression of His6-tagged IMPDHs in Escherichia
coli were created by inserting the IMPDH coding sequences
into pET28a that had been converted into a USER-compatible
vector (see Supplementary Figure S1 at http://www.BiochemJ.
org/bj/441/bj4410219add.htm). pET28U was created by PCR-
amplifying pET28 with the primers BGHA527/BGHA528
followed by DpnI treatment to remove the PCR template (see
Supplementary Figure S1). The P. brevicompactum IMPDH-
B (PbIMPDH-B) gene was amplified from cDNA from
P. brevicompactum. Genes encoding A. nidulans IMPDH-A
(AnImdA), P. brevicompactum IMPDH-A (PbIMPDH-A), P.
chrysogenum IMPDH-A (PcIMPDH-A) and P. chrysogenum
IMPDH-B (PcIMPDH-B) were obtained from gDNA (genomic
DNA). In all cases, the three exons of each gene were individually
PCR-amplified and purified and subsequently USER-fused using
a method described previously [5,6].
The expression constructs for chimaeric and mutated IMPDHs
were created by fusing the two parts of the IMPDHs using the
USER fusion method to introduce the mutation in the primer
tail [6]. Chimaeric IMPDH of PbIMPDH-B (N-terminus) and
PbIMPDH-A (C-terminus) was created by USER-fusing two P.
brevicompactum IMPDH-B and IMPDH-A fragments, which
were PCR-amplified with primer pairs BGHA529/BGHA667
and BGHA668/BGHA540 respectively, into pET28U as
described above. Similarly, chimaeric IMPDH of PbIMPDH-A
(N-terminus) and PbIMPDH-B (C-terminus) was created by
amplifying PbIMPDH-A and PbIMPDH-B fragments with
primer pairs BGHA539/BGHA669 and BGHA670/BGHA530
respectively, followed by USER-fusing into pET28U. Using
gDNA from the proper source, the Y411F (Chinese-hamster
ovary IMPDH2 numbering) mutation was introduced into A.
nidulans IMPDH-A and into P. brevicompactum IMPDH-A and
IMPDH-B by amplifying and fusing two IMPDH fragments with
primer pairs BGHA545/BGHA359 and BGHA546/BGHA358;
BGHA539/BGHA455 and BGHA540/BGHA454; and
BGHA529/BGHA361 and BGHA530/BGHA360 respectively.
For details of primers, see Supplementary Tables S2
and S3 (at http://www.BiochemJ.org/bj/441/bj4410219add.
htm). The PfuX7 polymerase was used for PCR amplification in
all cases [7].
Cladistic analysis
Alignment of DNA coding regions and protein were performed
with ClustalW implemented in the CLC DNA Workbench 6
program (CLC bio) using the following parameters: gap open
cost = 6.0; gap extension cost = 1.0; and end gap cost = free.
A cladogram was constructed with the same software using the
neighbour-joining method and 1000 bootstrap replicates [33]. The
DNA sequence of IMPDH and β-tubulin from selected fungi were
either generated by dPCR (degenerate PCR) (see Supplementary
Table S1) or retrieved from the NCBI: A. nidulans β-tubulin
(GenBank® accession number XM_653694) and IMPDH-A
DNA sequence [GenBank® accession number BN001302
(ANIA_10476)]; Coccidioides immitis β-tubulin (GenBank®
accession number XM_001243031) and IMPDH-A DNA
sequence (GenBank® accession number XM_001245054);
Penicillium bialowiezense IBT21578 β-tubulin (GenBank®
accession number JF302653), IMPDH-A DNA sequence
(GenBank® accession number JF302658) and IMPDH-B
DNA sequence (GenBank® accession number JF302662); P.
brevicompactum IBT23078 β-tubulin (GenBank® accession
number JF302653) and IMPDH-A DNA sequence (GenBank®
accession number JF302657); Penicillium carneum IBT3472
β-tubulin (GenBank® accession number JF302650), IMPDH-A
DNA sequence (GenBank® accession number JF302656)
and IMPDH-B DNA sequence (GenBank® accession number
JF302660); P. chrysogenum IBT5857 β-tubulin (GenBank®
accession number XM_002559715), IMPDH-A DNA sequence
(GenBank® accession number XM_002562313) and IMPDH-B
DNA sequence (GenBank® accession number XM_002559146);
Penicillium paneum IBT21729 β-tubulin (GenBank® accession
number JF302651), IMPDH-A DNA sequence (GenBank®
accession number JF302654) and IMPDH-B DNA sequence
(GenBank® accession number JF302661); and Penicillium
roqueforti IBT16406 β-tubulin (GenBank® accession number
JF302649), IMPDH-A DNA sequence (GenBank® accession
number JF302655) and IMPDH-B DNA sequence (GenBank® ac-
cession number JF302659). The MPA gene cluster sequence from
P. brevicompactum IBT23078, which contains the IMPDH-B gene
sequence (mpaF) is available from GenBank® under accession
number HQ731031. Full-length protein sequences were retrieved
from the NCBI: Candida albicans: (GenBank® accession number
EEQ46038), Chinese-hamster ovary IMPDH2 (GenBank®
accession number P12269), E. coli (GenBank® accession number
ACI80035), human IMPDH type 2 (GenBank® accession num-
ber NP_000875), P. chrysogenum IMPDH-A gene (GenBank®
accession number CAP94756), IMPDH-B (GenBank® accession
number CAP91832), yeast IMD2 (GenBank® accession number
P38697), IMD3 (GenBank® accession number P50095), and
IMD4 (GenBank® accession number P50094).
dPCR
Primers and PCR conditions for amplifying part of the
genes encoding IMPDH-A, IMPDH-B and β-tubulin were
as described in [3]. Genomic DNA from 11 fungi
from the Penicillium subgenus Penicillium subclade (see
Supplementary Table S1) were extracted using the FastDNA®
SPIN for Soil Kit (MP Biomedicals). PCR primer pairs
BGHA236HC/BGHA246HC or BGHA531/BGHA532 were used
to amplify DNA from the gene encoding IMPDH-A. The
primer pair BGHA240HC/BGHA241HC was used to amplify
DNA from the gene encoding IMPDH-B, and the primer pair
BGHA343/BGHA344 was used to amplify β-tubulin.
Expression and purification of His6-tagged proteins
Plasmids were expressed in a guaB derivative of E. coli
BL21(DE3) [8]. Cells were grown in LB (Luria–Bertani) medium
at 30 ◦C until reaching a D600 of 1.0 for AnImdA and 1.5 for
c© The Authors Journal compilation c© 2012 Biochemical Society
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all other enzymes, and induced overnight at 16 ◦C with 0.5 mM
IPTG (isopropyl β-D-thiogalactopyranoside) for AnImdA and
0.1 mM IPTG for all other enzymes. Cells were harvested by
centrifugation at 3000 g for 20 min and resuspended in buffer
(pH 8.0) containing 20 mM sodium phosphate, 500 mM NaCl,
5 mM 2-mercaptoethanol, 5 mM imidazole and CompleteTM
protease inhibitor cocktail (Roche Diagnostics). Cell lysates were
prepared by sonication followed by centrifugation at 40000 g
for 30 min. All enzymes were purified using a HisTrap affinity
column (GE Healthcare) on an ¨AKTA Purifier (GE Healthcare)
and dialysed into buffer containing 50 mM Tris/HCl, pH 8.0,
100 mM KCl, 1 mM DTT (dithiothreitol) and 10% glycerol.
All enzymes were purified to >90% purity as determined
by SDS/PAGE (12% gels), with the exception of PcIMPDH-
B, which was only partially purified to ∼45% purity due to
poor expression and stability (see Supplementary Figure S2 at
http://www.BiochemJ.org/bj/441/bj4410219add.htm).
Enzyme concentration determination
Enzyme concentration was determined using the Bio-Rad
assay according to the manufacturer’s instructions using IgG
as a standard. The Bio-Rad assay overestimates the IMPDH
concentration by a factor of 2.6 [9]. Concentration of active
enzyme was determined by MPA titration using an equation for
tight binding inhibition (eqn 1):
vi/v0 = (1 − {([E] + [I] + IC50) − ({([E] + [I] + IC50)2}
−4E · [I])0.5}/(2[E])) (1)
Enzyme assays
Standard IMPDH assay buffer consisted of 50 mM Tris/HCl
(pH 8.0), 100 mM KCl, 1 mM DTT, and various concentrations
of IMP and NAD+ (concentrations used for each enzyme
are listed in Supplementary Table S4 at http://www.BiochemJ.
org/bj/441/bj4410219add.htm. Enzyme activity was measured
by monitoring the production of NADH by changes in
absorbance increase at 340 nm on a Cary Bio-100 UV–
visible spectrophotometer at 25 ◦C (ε340 = 6.2 mM− 1·cm− 1). MPA
inhibition assays were performed at saturating IMP and half-
saturating NAD+ concentrations to avoid complications arising
from NAD+ substrate inhibition. IMP-independent reduction of
NAD+ was observed in the partially purified preparation
of PcIMPDH-B at ∼25% of the rate in the presence of IMP.
The rate of this background reaction was subtracted from the rate
with IMP for each MPA concentration. Initial velocity data were
obtained by fitting to either the Michaelis–Menten equation (eqn
2) or an uncompetitive substrate inhibition equation (eqn 3) using
SigmaPlot (Systat Software).
v = Vm[S]/(Km + [S]) (2)
v = Vm/{1 + (Km/[S]) + ([S]/K ii)} (3)
Bacterial complementation assays
Cultures were grown overnight in LB medium with 25 μg/ml
kanamycin. Then, 5 μl of 1:20 serial dilutions was plated
on M9 minimal medium containing 0.5% casamino acids,
100 μg/ml L-tryptophan, 0.1% thiamine, 25 μg/ml kanamycin
and 66 μM IPTG. Guanosine-supplemented plates contained
50 μg/ml guanosine. MPA plates contained 100 μM MPA. Plates
were incubated overnight at 37 ◦C and then grown at room
temperature (25 ◦C).
Sequences generated in the present study
See Supplementary Table S1 for GenBank® accession numbers.
RESULTS
The presence of IMPDH-B is not linked to MPA biosynthesis
The first gene encoding IMPDH-B was identified in P.
brevicompactum where it is part of the MPA biosynthetic cluster
and confers MPA resistance (P. brevicompactum IMPDH-B
is also known as mpaF) [2]. Of the full genome sequences
currently available for filamentous fungi, only P. chrysogenum
(the sole representative of Penicillium subgenus Penicillium)
contains an IMPDH-B gene. We previously analysed four other
fungi in Penicillium subgenus Penicillium for the presence of
IMPDH genes, and all contain both IMPDH-A and IMPDH-
B [3]. We have now expanded this search to include 11
additional Penicillium strains of the Penicillium subgenus.
dPCR analysis revealed that all 11 strains contain both genes
encoding IMPDH-A and IMPDH-B (see Supplementary Table
S1 and Supplementary Figure S3 at http://www.BiochemJ.
org/bj/441/bj4410219add.htm), suggesting that the presence of
IMPDH-B is widespread in species of Penicillium subgenus
Penicillium, even though many of these strains do not produce
MPA [10].
It is possible that these MPA non-producer strains may
contain latent or cryptic MPA biosynthetic genes. A previously
described example is that although P. chrysogenum does not
produce viridicatumtoxin, griseofulvin and tryptoquialanine, it
does contain sequence regions with high identity with these
biosynthetic clusters, which suggests that these gene functions
were lost during evolution [11,12]. Likewise, P. chrysogenum does
not produce MPA. However, in this case, BLAST searches failed
to identify any genes with significant sequence identity with the
MPA biosynthesis gene cluster in P. chrysogenum. These searches
did identify an IMPDH-B pseudogene in P. chrysogenum. This
260 bp gene fragment has highest identity with IMPDH-B from
P. chrysogenum (77%) and 64% identity with IMPDH-B
from P. brevicompactum.
We analysed the regions surrounding the MPA biosynthetic
cluster in P. brevicompactum and used BLAST searches to
identify similar genes in P. chrysogenum. In this way, adjacent
genes that are highly similar and syntenic to genes found in
P. chrysogenum were identified (Figure 1). Interestingly, the
genes flanking one side of the cluster correspond to a locus on
contig Pc0022, while the other side of the cluster corresponds
to a locus located at another contig, Pc0021. Regions further
away from the MPA cluster in P. brevicompactum contain
additional homologues of P. chrysogenum genes, but these genes
are located in many different contigs (see Supplementary Table
S5 at http://www.BiochemJ.org/bj/441/bj4410219add.htm). P.
chrysogenum contains small sequence regions with high identity
with the flanking region of the MPA cluster. This
identity is in the promoter regions and probably represents
conserved regulatory regions. Despite a detailed search, we found
no sequence similarity to the regions around the PcIMPDH-B
and the pseudo IMPDH-B (Pc22g07570) (results not shown).
Together, these findings suggest that the MPA cluster has never
been present in P. chrysogenum and that a high degree of genome
shuffling has occurred since the divergence of P. brevicompactum
and P. chrysogenum.
c© The Authors Journal compilation c© 2012 Biochemical Society
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Figure 1 Flanking regions of the MPA-biosynthesis gene cluster
P. brevicompactum and the corresponding syntenic loci on P. chrysogenum contigs Pc0022 and Pc0021 are shown. Regions marked with (*) indicate short conserved sequences (length <53 bp,
identity >86 %).
Figure 2 MPA resistance in fungi and bacteria expressing fungal IMPDHs
(A) Spot assay to determine sensitivity towards MPA. A 10-fold dilution series of spores from A. nidulans, P. chrysogenum and P. brevicompactum were grown on CYA plates containing no additives
or 6.2 μM MPA. The spot with the highest number of spores in each row contains ∼106 spores. (B) E. coli guaB was cultured on minimal medium, with no additions or supplemented with
100 μM MPA or 50 μg/ml guanosine (Guo) and 100 μM MPA.
PbIMPDH-B is MPA-resistant, but PcIMPDH-B is MPA-sensitive
The PbIMPDH-B gene confers MPA resistance on A. nidulans,
suggesting that MPA resistance might be a common feature of
all IMPDH-B proteins [3]. Consistent with this hypothesis, P.
chrysogenum is less sensitive to MPA than A. nidulans, although
significantly more sensitive than P. brevicompactum (Figure 2A).
These observations suggest that P. chrysogenum IMPDH-B may
be semi-resistant to MPA.
To investigate this hypothesis further, IMPDHs from P.
brevicompactum, P. chrysogenum and A. nidulans were
heterologously expressed as N-terminal His6-tagged proteins in
an E. coli guaB strain that lacks endogenous IMPDH; these
enzymes are denoted PbIMPDH-A, PbIMPDH-B, PcIMPDH-
A, PcIMPDH-B and AnImdA (Figure 2B). All strains grow
on minimal medium in the presence of guanosine (Figure 2B).
Bacteria expressing AnImdA, PbIMPDH-A, PbIMPDH-B and
PcIMPDH-A grow on minimal medium in the absence of
guanosine, indicating that active IMPDHs were expressed in all
four cases. Only bacteria expressing PbIMPDH-B were resistant
to MPA (Figure 2B). PcIMPDH-B failed to grow on minimal
medium in the absence of guanosine, suggesting that this protein
was not able to complement the guaB deletion. This observation
suggests that PcIMPDH-B may be non-functional.
All five fungal IMPDHs were isolated to investigate further
the molecular basis of MPA resistance. With the exception of
PcIMPDH-B, all enzymes were purified to >90% purity in one
step using a nickel-affinity column (see Supplementary Figure
S2). PcIMPDH-B was unstable and could only be purified to
∼45% homogeneity. Western blot analysis using anti-(human
IMPDH2) polyclonal antibodies showed that PcIMPDH-B had
undergone proteolysis. This degradation could not be prevented
by the inclusion of protease inhibitor cocktails during the
purification. We performed MPA titrations to determine
the concentration of active enzyme in all five protein samples.
MPA traps an intermediate in the IMPDH reaction, so that only
active enzyme will bind MPA [13]. All of the proteins were
∼100% active, with the exception of PcIMPDH-B, which was
48% active, as expected. The oligomeric states of AnImdA,
PbIMPDH-A and PbIMPDH-B were examined by gel-filtration
chromatography. All three enzymes eluted at a molecular mass
of approximately 220 kDa, consistent with being tetramers (see
Supplementary Figure S3).
AnImdA, PcIMPDH-A and PcIMPDH-B are all sensitive to
MPA, with values of IC50 ranging from 26 to 60 nM (Figure 3
and Table 1). Similar MPA inhibition has been reported for the
mammalian and C. albicans enzymes [13,14]. These observations
indicate that MPA resistance is not a general property of IMPDH-
Bs.
MPA is a poor inhibitor of both PbIMPDH-A and PbIMPDH-B
(Figure 3 and Table 1). PbIMPDH-A is 10-fold more resistant than
IMPDHs from the other filamentous fungi whereas PbIMPDH-B
is a remarkable ∼1000-fold more resistant. Thus the ability of
P. brevicompactum to proliferate while producing MPA can be
explained by the intrinsic resistance of its target enzymes. These
observations suggest that MPA production creates a selective
c© The Authors Journal compilation c© 2012 Biochemical Society
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Table 1 Characterization of IMPDHs from filamentous fungi
Data were analysed as described in the Experimental section. n.a., not applicable. PbIMPDH-B and PcIMPDH-B did not show NAD+ substrate inhibition up to 5 mM. The concentrations of IMP and
NAD+ used for IC50 determination for each enzyme is included in Supplementary Table S4 at http://www.BiochemJ.org/bj/441/bj4410219add.htm.
Enzyme IC50 (MPA) (μM) k cat (s− 1) K m (IMP) (μM) k cat/K m (IMP) (M− 1·s− 1) K m (NAD+ ) (μM) k cat/K m (NAD) (M− 1·s− 1) K ii (NAD+ ) (mM)
AnImdA 0.026 +− 0.002 0.74 +− 0.06 10 +− 1 74000 +− 8000 170 +− 70 4400 +− 100 1.5 +− 0.6
PbIMPDH-A 0.43 +− 0.03 0.70 +− 0.08 130 +− 30 5400 +− 1200 340 +− 90 2100 +− 900 4.7 +− 1.1
PbIMPDH-B 27 +− 9 0.41 +− 0.02 1400 +− 200 300 +− 80 790 +− 140 500 +− 100 n.a.
PcIMPDH-A 0.036 +− 0.004 0.84 +− 0.03 40 +− 6 21000 +− 2000 290 +− 60 2900 +− 300 2.4 +− 0.5
PcIMPDH-B 0.06 +− 0.01 0.0075 +− 0.001 600 +− 300 12 +− 3 640 +− 130 11 +− 6 n.a.
Figure 3 MPA inhibition of fungal IMPDHs
, AnImdA;, PbIMPDH-A;, PbIMPDH-B; , PcIMPDH-A;, PcIMPDH-B.
pressure on IMPDH evolution. Curiously, similar IC50 values have
been reported for Imd2 and Imd3 from Saccharomyces cerevisiae
(IC50 = 70 μM and 500 nM for Imd2 and Imd3 respectively
[15]). These enzymes are the only other examples of naturally
occurring MPA-resistant IMPDHs from eukaryotes. Cladistic
analysis indicates that the S. cerevisiae IMPDHs arose in a distinct
gene-duplication event (Figure 4). Therefore P. brevicompactum
IMPDH-B is unlikely to share a common ancestry with S.
cerevisiae Imd2.
IMPDH-Bs are very poor IMPDHs
The reactions of the fungal IMPDHs were characterized to
determine how MPA resistance affects enzymatic function. The
values of kcat are similar for AnImdA, PcIMPDH-A, PbIMPDH-A
and PbIMPDH-B, and generally typical for eukaryotic IMPDHs
[13] (Table 1). Typical values of Km (NAD+ ) and Km (IMP) are
also observed for AnImdA and PcIMPDH-A; the values of Km
for PbIMPDH-A are high, but not unprecedented. In contrast,
the value of Km (IMP) for PbIMPDH-B (1.4 mM) is ∼100-fold
higher than the highest value reported for any other IMPDH. Like
PbIMPDH-B, PcIMPDH-B exhibits an abnormally high value
of Km (IMP). The value of kcat of PcIMPDH-B is more than a
factor of 100 less than those of the other fungal IMPDHs. The
corresponding values of kcat/Km are the lowest ever observed for
an IMPDH by factors of 1000 (IMP) and 200 (NAD+ ) (see [13]
for compilation of values). Therefore both IMPDH-Bs are inferior
enzymes.
Identification of a major determinant of MPA resistance
MPA inhibits IMPDHs by an unusual mechanism [16]. The
IMPDH reaction proceeds via the covalent intermediate E-XMP*,
which forms when the active-site cysteine residue attacks the
C2 position of IMP, transferring a hydride to NAD+ [13].
The resulting NADH dissociates, allowing MPA to bind to E-
XMP*, preventing hydrolysis to form XMP. The crystal structure
of the E-XMP*–MPA complex has been solved for Chinese-
hamster ovary IMPDH type 2 [17], revealing that MPA stacks
against the purine ring of E-XMP* in a similar manner to the
nicotinamide of NAD+ . Surprisingly, all of the residues within
4 Å (1 Å = 0.1 nm) of MPA are completely conserved in the
fungal IMPDHs (Figure 5). Likewise, the IMP-binding site is also
highly conserved. Only residue 411 is variable (Chinese-hamster
ovary IMPDH2 numbering); the IMPDH-A enzymes contain a
tyrosine residue at this site, whereas IMPDH-B enzymes have
phenylalanine residues (Figure 5). Substitution of phenylalanine
for Tyr411 did not increase the MPA resistance of PbIMPDH-A,
nor did the substitution of tyrosine for Phe411 decrease the MPA
resistance of PbIMPDH-B (Table 2). Therefore the structural
determinants of MPA resistance must reside outside the active site.
Inspection of the structure suggested that the C-terminal
segment (residues 498–527) was another likely candidate for
a structural determinant of MPA resistance (Figure 5). This
region includes part of the site that binds a monovalent cation
activator, as well as segments that interact with the active site
residues. Deletion of this segment inactivates the enzyme [18].
Swapping the 30-residue C-terminal segments revealed that this
region is responsible for ∼7 of the 60-fold difference in MPA
resistance between PbIMPDH-A and PbIMPDH-B (see Table 2).
Additional structural determinants of MPA resistance remain to be
identified.
DISCUSSION
Phylogenetic analysis indicates that the IMPDH gene was
duplicated before the radiation of Penicillium subgenus
Penicillium (Figure 4 and see Supplementary Figure S4 at http://
www.BiochemJ.org/bj/441/bj4410219add.htm). No remnants of
the MPA biosynthetic cluster are present in P. chrysogenum,
which suggests that the ability to produce MPA arrived after
duplication of the IMPDH genes. Consistent with this hypothesis,
both IMPDHs from the MPA-producer P. brevicompactum are
more resistant to MPA than the IMPDHs from A. nidulans
and P. chrysogenum. Thus both P. brevicompactum IMPDH-
A and IMPDH-B have evolved in response to the presence
of MPA. PbIMPDH-B is 1000-fold more resistant than typical
eukaryotic IMPDHs. The structural basis of these functional
differences is not readily discernible. Whereas prokaryotic
IMPDHs contain substitutions in their active sites that can account
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Figure 4 IMPDH phylogeny
(A) Rooted cladogram based on full-length amino acid sequences. (B and C) Rooted cladograms based on (B) IMPDH cDNA sequences (372–387 bp) and (C) β-tubulin cDNA sequences (950 bp)
from eight species from Penicillium subgenus Penicillium and two filamentous fungi outside. P., Penicillium and A., Aspergillus. Bootstrap values (expressed as percentages of 1000 replications)
are shown at the branch points, and the scale represents changes per unit. In (B), MPA production is indicated by + or − . The subclades with Penicillium subgenus Penicillium genes are marked
in light grey (IMPDH-A) and dark grey (IMPDH-B). E. coli has been used as an outgroup in (A), and C. immitis as an outgroup in (B) and (C).
for MPA resistance, no such substitutions are present in the P.
brevicompactum IMPDHs. The substitution of serine or threonine
for Ala249 is associated with MPA resistance in C. albicans and
S. cerevisiae [14,15]. This substitution is found in PbIMPDH-
A, but not in the more resistant PbIMPDH-B. Substitutions at
positions 277 and 462 have also resulted in modest MPA resistance
[19], and substitutions at position 351 are proposed to cause
resistance [20], but again no correlation is observed in the fungal
IMPDHs. We identified the C-terminal segment as a new structural
determinant of MPA sensitivity, but this segment accounts for
only 7 of the 60-fold difference in resistance between PbIMPDH-
B and PbIMPDH-B. Importantly, the extraordinary resistance of
PbIMPDH-B comes with a catalytic cost as this enzyme has lost
much of the catalytic power of a typical IMPDH, with values of Km
(IMP) that are ∼100-fold greater and kcat/Km (IMP) that are 100–
1000-fold lower than ‘normal’. This observation suggests that
PbIMPDH-B would be a very poor catalyst at normal cellular IMP
concentrations of 20–50 μM [21]. However, IMP concentrations
increase 10–35-fold in the presence of MPA [1,22,23]. Thus P.
brevicompactum may contain millimolar concentrations of IMP
during MPA biosynthesis, so that the turnover of PbIMPDH-B
would be comparable with a ‘normal’ fungal IMPDH.
Curiously, MPA production does not follow the phylogenetic
relationship established by analysis of the IMPDH and β-
tubulin genes (Figure 4). P. chrysogenum does not contain
MPA-biosynthetic genes, although MPA producers are found
on the neighbouring branches of the phylogenetic tree. As
noted above, P. chrysogenum is more resistant to MPA than
is A. nidulans (Figure 2A). This resistance could be the result
of a gene-dosage effect as MPA resistance is associated with
amplification of IMPDH genes in several organisms, consistent
with this hypothesis [20,24–27]. We propose that the presence
of two IMPDH genes in Penicillium subgenus Penicillium was
permissive for MPA production. The failure to observe MPA
production in other Penicillium species may reflect inappropriate
culture conditions rather than absence of the biosynthetic cluster.
If so, it is possible that MPA biosynthesis has been obtained
in several independent events. It will be interesting to map the
evolution of MPA biosynthesis and resistance as more genomic
sequences of filamentous fungi become available.
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Figure 5 The MPA-binding site is conserved among drug-sensitive and drug-resistant eukaryotic IMPDHs
(A) Amino acid polymorphism in IMPDH of A. nidulans (An), P. brevicompactum (Pb) and P. chrysogenum (Pc). Shown are residues within 4 A˚ of E-XMP* (XMP*) and MPA. Residues in red are
polymorphic between IMPDH-A and IMPDH-B. (B) An alignment of IMPDH-A and IMPDH-B from P. brevicompactum 23078 and P. chrysogenum, IMPDH-A from A. nidulans and IMPDH2 from
Chinese-hamster ovary (CHO) was mapped on to the X-ray crystal structure of the MPA complex of Chinese-hamster ovary IMPDH (PDB code 1JR1) [17]. Key: 100 % conserved, dark magenta;
58 % conserved, tan; 17 % conserved, dark cyan. MPA, green ball and stick; IMP intermediate, grey ball and stick; K+ , gold; residues within 4 A˚ of MPA and IMP are shown in stick form. (C)
Alignment of the C-terminal region. The region aligned represents the fragments that were swapped in the chimaeric PbIMPDH-A and PbIMPDH-B.
Table 2 MPA inhibition of fungal IMPDH variants
Phe411 is replaced with tyrosine in IMPDH-B and Tyr411 is replaced by phenylalanine in
IMPDH-A*. nd, no data.
IC50 (μM)
Enzyme Wild-type 411* C-terminal swap C-terminal swap + 411*
PbIMPDH-A 0.43 +− 0.03 0.16 +− 0.02 3 +− 0.2 4.1 +− 0.3
PbIMPDH-B 27 +− 9 25 +− 2 4.1 +− 0.3 3.1 +− 0.3
AnImdA 0.026 +− 0.002 0.026 +− 0.002 nd nd
Gene duplication is generally believed to be a driving force
in evolution, allowing one copy to diverge constraint-free,
while the other copy maintains essential functions. The ‘escape
from adaptive conflict’ subfunctionalization model is particularly
attractive for the evolution of new enzyme activities [28,29]. In
this model, duplication relieves the constraint of maintaining the
original function and allows the emergence of enzymes with new
catalytic properties. The blemish in this appealing hypothesis has
long been recognized: most mutations are deleterious, so that
the extra copy is quickly lost or converted into a pseudogene.
Although several elegant and rigorous investigations of the
in vitro evolution of new enzyme function demonstrate
the feasibility of subfunctionalization (reviewed in [29,30]),
genetic drift is widely recognized as the dominant mechanism
in the wider evolution field. Several observations suggest that the
emergence of MPA-resistant PbIMPDH-B could be an example
of neofunctionalization by a classic Ohno-type mechanism: a
duplication followed by (largely deleterious) drift until a new
environment, MPA production, provides a selection.
PcIMPDH-B displays the effects of deleterious genetic drift:
this protein is labile to proteolysis, and the value of kcat ∼1%
of that of typical eukaryotic IMPDH. Microarray data indicate
that P. chrysogenum expresses both IMPDH-A and IMPDH-B
under most conditions, so at present there is no evidence for
specialized functions for these genes [31,32]. We cannot rule out
the possibility that PcIMPDH-B plays another role within the
cell, perhaps by interacting with another protein, or even as a
heterotetramer with PcIMPDH-A. Nevertheless, our data suggest
that the enzymatic properties of both IMPDH-Bs have declined
over the course of evolution. In the case of P. brevicompactum,
gaining the ability to produce MPA may have rescued IMPDH-B
from non-functionalization.
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Figure S1 Detailed graphical representation showing the principle of PCR-based USER cloning of a GOI (gene of interest) into pET28a
A pET28a USER-compatible vector fragment, pET28aU, is made by PCR amplification using uracil-containing primers (527 and 528) followed by DpnI treatment to remove the PCR template. Likewise,
the GOI fragment to be inserted into pET28aU is amplified with primers containing uracil. The primer tails were designed to allow seamless USER fusion; the uracil in the 5′-end of the GOI fragment
corresponds to the T of the start codon (ATG) of the GOI, and the uracil in the 3′-end of the GOI fragment is complementary to the second nucleotide in the stop codon (TAG) of pET28a. USER fusion
of the GOI PCR fragment and pET28aU is performed by mixing the two fragments, followed by USER enzyme treatment to remove uracil residues. This step generates ends with single-stranded DNA
overhangs that allow for orderly fusion of the fragments. Following USER treatment, the cloning mixture is transformed into E. coli.
Figure S2 SDS/PAGE of purified recombinant fungal proteins
Lanes contents are as marked. All enzymes were purified to >90 % purity, with the exception of PcIMPDH-B, which was only partially purified to ∼45 % purity because of poor stability. Note that the
lower-molecular-mass bands in the PcIMPDH-B sample are also IMPDH, as demonstrated by Western blot analysis. The concentrations of all enzymes were verified by titration with MPA as described
in the main paper. This proteolysis could not be prevented with the addition of protease inhibitor cocktails to the lysate. P135, PbIMPDH-B with PbIMPDH-A C-terminus; P136, PbIMPDH-B with
PbIMPDH-A C-terminus + F411Y mutation; P137, PbIMPDH-A with PbIMPDH-B C-terminus; P138, PbIMPDH-A with PbIMPDH-B C-terminus + Y411F mutation; P118, Pb IMPDH-A with Y411F
mutation; P119, PbIMPH-B with F411Y mutation; P120, AnImdA with Y411F mutation. Molecular masses are indicated in kDa.
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Figure S3 Determination of IMPDH oligomeric state using gel filtration
chromatography on a S200 Sephacryl column
AnImdA (dotted line) elutes at 39.3 ml, PbIMPDH-A (continuous line) elutes at 39.2 ml, and
PbIMPDH-B (dashed line) elutes at 39.0 ml. All three proteins elute at ∼220 kDa, consistent
with their being tetramers. The elution volumes (Ve) of the standards are as follows: Blue Dextran,
36 ml; thyroglobulin, 670 kDa, 36.2 ml; bovine γ -globulin, 158 kDa, 44 ml; chicken ovalbumin,
44 kDa, 56.9 ml; equine myoglobin, 17 kDa, 71.8 ml; vitamin B12, 1.35 kDa, 117 ml.
Figure S4 Rooted cladogram based on β-tubulin cDNA sequences (950 bp) from 14 species from Penicillium subgenus Penicillium and two other filamentous
fungi
P., Penicillium; A., Aspergillus. MPA production is indicated by + or − . The grey line indicates organisms where both IMPDH-A and IMPDH-B genes have been detected. Bootstrap values
(expressed as percentages of 1000 replications) are shown at the branch points, and the scale represents changes per unit. Coccidioides immitis has been used as an outgroup.
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Table S1 Sequences generated in the present study
DNA sequences (GenBank® accession number)
Species IBT number Other collection numbers MPA production* IMPDH-A IMPDH-B β-Tubulin
P. allii 20212 CBS 875.95 − JN112053 JN112066 JN112035
P. albocoremium† 21596 − − JN112054 JN112065 JN112036
P. aurantiogriseum† 11325 CBS 792.95 − JN112050 JN112062 JN112033
P. brevicompactum† 18329 CBS 110067 ++ JN112046 JN112068 JN112040
P. caseifulvum 19782 CBS 108956 − JN112051 JN112067 JN112037
P. crustosum 21518 CBS 101025 − JN112048 JN112061 JN112030
P. cyclopium† 16769 CBS 110337 − JN112049 JN112063 JN112034
P. echinulatum† 21839 CBS 112286 − JN112052 JN112064 JN112032
P. roqueforti 14756 − + JN112045 JN112058 JN112039
P. roqueforti† 24748 − − JN112044 JN112059 JN112038
P. viridicatum 21551 CBS 101034 − JN112047 JN112060 JN112031
*MPA production on CYA medium: − , no production; + , medium production; ++ , high production [1].
†The extracted imdA and imdB sequence parts for these organisms do not overlap and are therefore not included in Figure 5(B) of the main text.
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Table S2 PCR primers
Underlined sequence will be removed and lead to a single-stranded overhang during USER
cloning.
Primer Sequence (5′→3′)
BGHA358 AGGCCAGCUCGTGAAAGCCTTCCGTGGTATG
BGHA359 AGCTGGCCUTCGTTGCTGACAAAGTACTC
BGHA360 AGGTCAGCUGGTCAAGGCCTACCGCGGTATG
BGHA361 AGCTGACCUTCATTGCTAACGTAGTACTC
BGHA430 AAGCCGATGUAACCGGGCAGGATCAGGA
BGHA431 ACATCGGCTUCCCCGCTTCCGATGTCTCATTG
BGHA432 AGGGTTCCGTTCUCAGTGACAGGGAAGCCACCGAAG
BGHA433 AGAACGGAACCCUTAAGTCCAAGCTCGTTGGA
BGHA434 AAGGTGAUAGAACCGGGCAAAATCAGGA
BGHA435 ATCACCTUCCCGGCATCGGATGTTTCGT
BGHA436 AGGGTTCCCTTTUCGGTCACCGGGAACCCGCCGA
BGHA437 AAAAGGGAACCCUCCTCTCGAAGCTTCTCGGA
BGHA454 ACGGAAGGCCUTGACGAGCTGGCCCTCGTTG
BGHA455 ATTGGGGTGGCCTCUCTCATGAGCACTGAAGTTCTTTC
BGHA505 AGCCGATGUAGCCGGGCAAGATCAGGA
BGHA506 ACATCGGCUTCCCTGCCTCCGATGTGT
BGHA507 AGTTCCGTUCTCAGTGACAGGGAAACCTCC
BGHA508 AACGGAACUCTTCGCTCCAAGCTCGTT
BGHA509 AACCGATAUATCCCGGAAGAATGAGGAA
BGHA510 ATATCGGTUTTCCTGCTTCCGATGTTAC
BGHA511 ATTTTCAGUAACTGGGAAGCCGCCGAA
BGHA512 ACTGAAAAUGGAACTCTCCGCTCAAAG
BGHA527 ATATGGCUGCCGCGCGGCACC
BGHA528 AGATCCGGCUGCTAACAA
BGHA529 AGCCATAUGGTCGAAATCCTGGACTA
BGHA530 AGCCGGATCUAAGAAGAGTACAACTTCTTCTCG
BGHA539 AGCCATAUGCCTATCACCGCCAGCGAC
BGHA540 AGCCGGATCUACGCGTAAAGCTTCTTGTCG
BGHA541 AGCCATAUGGTCGAAGTTCTGGATTATAC
BGHA542 AGCCGGATCUAAGAGTACAACTTCTTCTC
BGHA543 AGCCATAUGCCTATCACCGCCGGCGAC
BGHA544 AGCCGGATCUACGAGTAAAGCTTCTTGTC
BGHA545 AGCCATAUGCCAATTGCCAACGGTGAC
BGHA546 AGCCGGATCUAAGAGTAGAGCTTCTTGTC
BGHA667 ACGGTTCCGUTGTTCACACCGGTGTGCA
BGHA668 ACGGAACCGUTCGCTTTGAAATGCGCAG
BGHA669 ACCTGGCCGUTGTCGACACCAGCGTGCA
BGHA670 ACGGCCAGGUTCGCTTTGAGATGAGAAG
BGHA236HC ATGCCIATYNCCRMCGGIGAYKC
BGHA246HC CRGCCTTCTTRTCCTCCATGG
BGHA531 AGCTTCTTGTCGTAGCTGTG
BGHA532 GTCAAGGGTCTSGCYATGG
BGHA240HC ATGGTCGADRTYCWGGAYTAYACC
BGHA241HC GARGCRCCRGCGTTMTTG
BGHA343 GAGCGYATGARYGTYTAYTTCA
BGHA344 GTGAACTCCATCTCRTCCATACC
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Table S3 E. coli expression constructs and cloning strategy
Primers for IMPDH amplification
Construct Enzyme expressed Exon 1 Exon 2 Exon 3
P113 PbIMPDH-A BGHA539/BGHA505 BGHA506/BGHA507 BGHA508/BGHA540
P114 PbIMPDH-B Amplified from cDNA with BGHA529/BGHA530
P115 A. nidulans ImdA BGHA545/BGHA509 BGHA510/BGHA511 BGHA512/BGHA546
P116 PcIMPDH-A BGHA543/BGHA430 BGHA431/BGHA432 BGHA433/BGHA544
P117 PcIMPDH-B BGHA541/BGHA434 BGHA435/BGHA436 BGHA437/BGHA542
P118 PbIMPDH-A with Y411F mutation BGHA539/BGHA455 and BGHA540/BGHA454 and P113 as PCR template
P119 PbIMPDH-B with F411Y mutation BGHA529/BGHA361 and BGHA530/BGHA360 and P114 as PCR template
P120 AnImdA with Y411F mutation BGHA545/BGHA359 and BGHA546/BGHA358 and P115 as PCR template
P135 Chimaeric IMPDH of PbIMPDH-B (N-terminus) and PbIMPDH-A C-terminus PbIMPDH-B and PbIMPDH-A fragments amplified with primer pairs
BGHA529/BGHA667 and BGHA668/BGHA540 respectively
P136 PbIMPDH-B with F411Y mutation and PbIMPDH-A C-terminus Same as for P135, but using P119 as PCR template for IMPDH-B fragment
P137 Chimaeric IMPDH of PbIMPDH-A (N-terminus) and PbIMPDH-B C-terminus PbIMPDH-A and PbIMPDH-B fragments amplified with primer pairs
BGHA539/BGHA669 and BGHA670/BGHA530 respectively
P138 PbIMPDH-A with Y411F mutation and with PbIMPDH-B C-terminus Same as for P137, but using P118 as PCR template for IMPDH-A fragment
Table S4 Concentrations of IMP and NAD+ used for determination of IC50
(MPA)
Enzyme IMP (mM) NAD+ (mM)
AnImdA 0.5 0.5
PbIMPDH-A 3 1
PbIMPDH-B 3 1
PcIMPDH-A 1 1
PcIMPDH-B 1 1
Mutant proteins 1 1
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Table S5 Putative genes flanking the MPA cluster in P. brevicompactum
Further comparison of the regions further away from the MPA cluster in P. brevicompactum reveal other genes homologous with genes from P. chrysogenum; however, they are located in loci of
many different contigs.
Gene
Region on P. brevicompactum
contig (Pb BAC 1E13 + 1C23)*
Size (number of amino
acids) BLASTx homologue Predicted function E-value Identity (%)
orf1 0–4139 987 P. chrysogenum, Pc22g22260 C2H2 finger domain protein 0 87
orf2 4513–5736 407 P. chrysogenum, Pc22g22270 DNA mismatch repair protein 1.15 × 10− 151 76
orf3 7554–9212 514 P. chrysogenum, Pc22g22280 WD repeat protein 0 94
orf4 10249–10913 191 P. chrysogenum, Pc22g22290 IgE-binding protein 5.97 × 10− 75 82
orf5 12809–1399 360 Neosartorya fischeri,
XP_001265454
Nucleoside diphosphatase 1.42 × 10− 113 71
P. chrysogenum, Pc22g22320 Nucleoside diphosphatase 1.37 × 10− 93 72
MPA cluster (17830– 43315)
orf13 50594–51894 368 P. chrysogenum, Pc21g04710 Phospho-2-dehydro-3-
deoxyheptonate
aldolase
0 94
orf14 52993–53878 256 P. chrysogenum, Pc21g04720 Unknown 4.00 × 10− 91 72
orf15 54299–55162 251 P. chrysogenum, Pc21g04730 Unknown 1.61 × 10− 63 60
orf16 55381–56121 246 Aspergillus fumigatus,
XP_001481519 (no hits in P.
chrysogenum)
Glycosidase hydrolase 1.00 × 10− 61 57
orf17 57170–59032 597 P. chrysogenum, Pc21g04750 C6 transcription factor 0 81
orf18 60261–62432 539 P. chrysogenum, Pc21g04770 NADH-cytochrome B5 reductase 6.63 × 10− 115 76
orf19 63597–65642 625 P. chrysogenum, Pc21g04800 Unknown 0 73
orf20 67638–68559 286 P. chrysogenum, Pc12g02580 Unknown 3.54 × 10− 44 62
orf21 68851–72867 1255 P. chrysogenum, Pc12g02550 Myosin protein 0 93
orf22 74083–79557 1181 P. chrysogenum, Pc22g21120 Carboxypeptidase 0 79
orf23 79786–82071 689 P. chrysogenum, Pc12g02500 Arginine permease 0 85
orf24 84043–85074 293 Aspergillus niger,
XP_001391260 (no hits in P.
chrysogenum)
Phytanoyl-CoA dioxygenase 3.30 × 10− 130 74
orf25 85889–91912 1907 Aspergillus terreus,
XP_001209574
Unknown 0 37
P. chrysogenum, Pc21g03870 Unknown 9.85 × 10− 142 27
orf26 93143–100908 2119 Penicillium marneffei,
XP_002147174
β-Galactosidase 0 74
P. chrysogenum, Pc22g14540 β-Galactosidase 0 38
orf27 101641–103365 574 P. chrysogenum, Pc21g21450 Unknown 0 61
REFERENCE
1 Frisvad, J. C. and Samson, R. A. (2004) Polyphasic taxonomy of Penicillium subgenus
Penicillium: a guide to identification of food and air-borne terverticillate Penicillia and their
mycotoxins. Stud. Mycol. 49, 1–174
Received 15 July 2011/31 August 2011; accepted 15 September 2011
Published as BJ Immediate Publication 15 September 2011, doi:10.1042/BJ20111278
c© The Authors Journal compilation c© 2012 Biochemical Society
